CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale SVP, General Counsel sold 6,404 shares at $1.71 ($10,951)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,361 shares at $1.73 ($7,545)
- 4 Open-market sale Chief Technical Officer sold 14,746 shares at $1.71 ($25,216)
- 4 Open-market sale President and CEO sold 46,003 shares at $1.68 ($77,285)
- 4 Open-market sale EVP of R&D sold 18,832 shares at $1.70 ($32,014)
- 4 Grant or award SVP, General Counsel acquired 144,928 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 173,913 shares (grant or award)
- 4 Grant or award SVP, Finance acquired 36,232 shares (grant or award)
- 4 Grant or award EVP of R&D acquired 173,913 shares (grant or award)
- 4 Grant or award Director acquired 369,957 shares (grant or award)
- 4 Grant or award President and CEO acquired 552,174 shares (grant or award)
- 4 Open-market sale EVP of R&D sold 27,199 shares at $1.78 ($48,414)
- 4 Planned sale Director sold 9,136 shares at $2.18 ($19,916)
- 4 Open-market sale Director sold 9,221 shares at $2.16 ($19,917)
- 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 36,404 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, General Counsel gave up 28,310 shares (to pay taxes)
- 4 Planned sale Director sold 18,641 shares at $2.28 ($42,488)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 3 of 14 · 275 filings